

# Icosapent Ethyl for CV Risk Reduction



**Icosapent ethyl can reduce triglyceride levels and CVD risk.**

It may also have anti-inflammatory, plaque- and membrane-stabilizing, and antioxidative properties.<sup>1</sup>

## Icosapent Ethyl for CV Risk Reduction<sup>2</sup>

### Efficacy

- Reduction in 5-point MACE
- Reduction in CV mortality

### Safety

- Higher rates of Afib/Aflutter, especially in patients with prior history
- Slight increase in primarily minor bleeding


## REDUCE-IT Trial



**A randomized control trial of 8,179 people from 11 countries**



**Compared icosapent ethyl with a placebo in patients with elevated TG levels on background statin therapy**




**Examined the impact of icosapent ethyl on cardiovascular disease**

## REDUCE-IT Showed Icosapent Ethyl:<sup>1</sup>



**Can reduce triglyceride levels by 20%**



**Can significantly lower cardiovascular risk (25% relative risk reduction)**



**Shows an acceptable safety profile**

**Icosapent ethyl was shown to reduce the risk of cardiovascular events.\***

**Other studies, like JELIS, Respect-EPA, CHERRY, and EVAPORATE, demonstrated consistent and beneficial effects on cardiovascular risk reduction and/or changes in plaque characteristics.**

*<sup>1</sup>However, the exact mechanisms of benefit are not completely elucidated, and icosapent ethyl may reduce CV events by a mechanism independent of triglyceride lowering.<sup>3</sup>*

### References

- <sup>1</sup> Bhatt, D.L. et al – Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. NEJM; 2018 [cited 2025 June 6th]. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMoa1812792>
- <sup>2</sup> Prakriti Gaba, Deepak L Bhatt, William E Boden, Icosapent ethyl for hypertriglyceridaemia and atherosclerosis: greater RESPECT for increased therapeutic use, European Heart Journal, Volume 45, Issue 6, 7 February 2024, Pages 439–442, <https://doi.org/10.1093/eurheartj/ehad668>
- <sup>3</sup> Aggarwal, R., et al – Triglycerides Revisited: A contemporary perspective on the assessment and management of cardiovascular risk due to elevated triglycerides: A consensus state of the International Atherosclerosis Society. IAS; 2024 [cited 2025 June 6th]. Available from [https://athero.org/wp-content/uploads/2024/07/IAS\\_Triglycerides-Revisited-Consensus\\_Aug2024.pdf](https://athero.org/wp-content/uploads/2024/07/IAS_Triglycerides-Revisited-Consensus_Aug2024.pdf)